Suppressive dendritic cells as a tool for controlling allograft rejection in organ transplantation: Promises and difficulties

被引：28

作者：

Ehser, Sandra ^{[1
]}

Chuang, Jing Jing ^{[1
]}

Kleist, Christian ^{[1
]}

Sandra-Petrescu, Flavius ^{[1
]}

Iancu, Mircea ^{[1
]}

Wang, Daohu ^{[1
]}

Opelz, Gerhard ^{[1
]}

Terness, Peter ^{[1
]}

机构：

[1] Heidelberg Univ, Inst Immunol, D-6900 Heidelberg, Germany

来源：

HUMAN IMMUNOLOGY | 2008年 / 69卷 / 03期

关键词：

dendritic cells; transplantation; tolerance; immunoregulation;

D O I：

10.1016/j.humimm.2008.01.018

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The most important antigen-presenting cells are dendritic cells (DCs), which play a central role in the initiation of immunity and tolerance. Their immunoregulatory properties offer the potential of donor-specific control of graft rejection after organ transplantation. It has not been clarified which DC subpopulations mediate tolerance, and the use of natural DCs for therapeutic applications is therefore problematic. Suppressive DCs can be generated in vitro by treating the cells with biologic, pharmacologic, or genetic agents. Here we discuss approaches for generating inhibitory DCs and present DC-based animal models for control of allograft rejection. A prerequisite of suppressive DCs for therapeutic application in clinical transplantation is a reproducible method for their generation as well as the induction of irreversible suppressive function. Based on lessons learned from the use of DCs as toots in clinical vaccine trials in cancer, we discuss the unknown aspects and risks of DC therapy in transplantation. (c) 2008 American Society for Histocompatibitity and Immunogenetics. Published by Elsevier Inc. All rights reserved.

引用

页码：165 / 173

页数：9

共 84 条

[1] Two lessons from the interface of genetics and medicine [J].

Allison, AC .

GENETICS, 2004, 166 (04) :1591-1599

[2] Is clinical tolerance realistic in the next decade? [J].

Ashton-Chess, Joanna ;

Brouard, Sophie ;

Soulillou, Jean-Paul .

TRANSPLANT INTERNATIONAL, 2006, 19 (07) :539-548

[3]

Banchereau J, 2001, CANCER RES, V61, P6451

[4] Immunobiology of dendritic cells [J].

Banchereau, J ;

Briere, F ;

Caux, C ;

Davoust, J ;

Lebecque, S ;

Liu, YT ;

Pulendran, B ;

Palucka, K .

ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+

[5] Dendritic cells and the control of immunity [J].

Banchereau, J ;

Steinman, RM .

NATURE, 1998, 392 (6673) :245-252

[6] Studying the immunosuppressive role of indoleamine 2,3-dioxygenase:: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo [J].

Bauer, TM ;

Jiga, LP ;

Chuang, JJ ;

Randazzo, M ;

Opelz, G ;

Terness, P .

TRANSPLANT INTERNATIONAL, 2005, 18 (01) :95-100

[7] Requirement of Rac1 and Rac2 expression by mature dendritic cells for T cell priming [J].

Benvenuti, F ;

Hugues, S ;

Walmsley, M ;

Ruf, S ;

Fetler, L ;

Popoff, M ;

Tybulewicz, VLJ ;

Amigorena, S .

SCIENCE, 2004, 305 (5687) :1150-1153

[8] Donor-specific allograft tolerance by administration of recipient-derived immature dendritic cells and suboptimal immunosuppression [J].

Bériou, G ;

Pêche, H ;

Guillonneau, C ;

Merieau, E ;

Cuturi, MC .

TRANSPLANTATION, 2005, 79 (08) :969-972

[9] Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-κB oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig [J].

Bonham, CA ;

Peng, LS ;

Liang, XY ;

Chen, ZY ;

Wang, LF ;

Ma, LL ;

Hackstein, H ;

Robbins, PD ;

Thomson, AW ;

Fung, JJ ;

Qian, SG ;

Lu, L .

JOURNAL OF IMMUNOLOGY, 2002, 169 (06) :3382-3391

[10] Aspirin-treated human DCs up-regulate ILT-3 and induce hyporesponsiveness and regulatory activity in responder T cells [J].

Buckland, M. ;

Jago, C. B. ;

Fazekasova, H. ;

Scott, K. ;

Tan, P. H. ;

George, A. J. T. ;

Lechler, R. ;

Lombardi, G. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (09) :2046-2059

← 1 2 3 4 5 6 7 8 9 →